GLYCOMIMETICS INC(NASDAQ:GLYC) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to GLYC. GLYC was compared to 571 industry peers in the Biotechnology industry. While GLYC seems to be doing ok healthwise, there are quite some concerns on its profitability. GLYC does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

GLYC had negative earnings in the past year.

In the past year GLYC has reported a negative cash flow from operations.

In the past 5 years GLYC always reported negative net income.

In the past 5 years GLYC always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -160.17%, GLYC is doing worse than 86.50% of the companies in the same industry.

GLYC has a Return On Equity of -194.94%. This is in the lower half of the industry: GLYC underperforms 69.09% of its industry peers.

		Industry Rank	Sector Rank
ROA	-160.17%
ROE	-194.94%
ROIC	N/A

ROA(3y)-79.61%

ROA(5y)-61.8%

ROE(3y)-94.21%

ROE(5y)-71.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GLYC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GLYC does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, GLYC has more shares outstanding

The number of shares outstanding for GLYC has been increased compared to 5 years ago.

GLYC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -29.36, we must say that GLYC is in the distress zone and has some risk of bankruptcy.

GLYC has a Altman-Z score of -29.36. This is amonst the worse of the industry: GLYC underperforms 90.59% of its industry peers.

GLYC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-29.36

ROIC/WACCN/A

WACC9.5%

2.3 Liquidity

A Current Ratio of 5.48 indicates that GLYC has no problem at all paying its short term obligations.

GLYC has a Current ratio (5.48) which is in line with its industry peers.

GLYC has a Quick Ratio of 5.48. This indicates that GLYC is financially healthy and has no problem in meeting its short term obligations.

GLYC has a Quick ratio (5.48) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	5.48
Quick Ratio	5.48

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GLYC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.15%.

The Revenue for GLYC has decreased by -87.50% in the past year. This is quite bad

GLYC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -90.05% yearly.

EPS 1Y (TTM)6.15%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-23.08%

Revenue 1Y (TTM)-87.5%

Revenue growth 3Y-90.05%

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

GLYC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.89% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-6.84%

EPS Next 2Y11.13%

EPS Next 3Y3.33%

EPS Next 5Y11.89%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

GLYC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year GLYC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y11.13%

EPS Next 3Y3.33%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for GLYC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GLYCOMIMETICS INC

NASDAQ:GLYC (2/18/2025, 4:35:55 PM)

After market: 0.34 -0.02 (-5.56%)

0.36

+0.07 (+24.14%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-08 2024-11-08/bmo

Earnings (Next)03-25 2025-03-25/amc

Inst Owners35.73%

Inst Owner Change70.54%

Ins Owners8.32%

Ins Owner Change0%

Market Cap23.21M

Analysts85.71

Price Target1.02 (183.33%)

Short Float %3.25%

Short Ratio2.78

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)2.67%

Min EPS beat(2)-1.01%

Max EPS beat(2)6.35%

EPS beat(4)3

Avg EPS beat(4)4.89%

Min EPS beat(4)-1.01%

Max EPS beat(4)10%

EPS beat(8)6

Avg EPS beat(8)9.84%

EPS beat(12)9

Avg EPS beat(12)8.53%

EPS beat(16)13

Avg EPS beat(16)8.92%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)33.33%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	2321.28
P/FCF	N/A
P/OCF	N/A
P/B	1.16
P/tB	1.16
EV/EBITDA	N/A

EPS(TTM)-0.61

EYN/A

EPS(NY)-0.44

Fwd EYN/A

FCF(TTM)-0.55

FCFYN/A

OCF(TTM)-0.55

OCFYN/A

SpS0

BVpS0.31

TBVpS0.31

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-160.17%
ROE	-194.94%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-79.61%

ROA(5y)-61.8%

ROE(3y)-94.21%

ROE(5y)-71.99%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	23.64%
Cap/Sales	213.6%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.48
Quick Ratio	5.48
Altman-Z	-29.36

F-Score4

WACC9.5%

ROIC/WACCN/A

Cap/Depr(3y)18.63%

Cap/Depr(5y)26.36%

Cap/Sales(3y)104.92%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)6.15%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-23.08%

EPS Next Y-6.84%

EPS Next 2Y11.13%

EPS Next 3Y3.33%

EPS Next 5Y11.89%

Revenue 1Y (TTM)-87.5%

Revenue growth 3Y-90.05%

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-4.11%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y40.22%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y40.18%

OCF growth 3YN/A

OCF growth 5YN/A

GLYCOMIMETICS INC (GLYC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens